The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection
Open accessAbstract
The activity of antibodies against filoviruses is poorly understood but has important consequences for vaccine design and passive prophylaxis. To investigate this activity, a panel of recombinant human monoclonal antibodies to Ebola virus antigens was isolated from phage display libraries constructed from RNA from donors who recovered from infection in the 1995 Ebola virus outbreak in Kikwit, Democratic Republic of Congo. Antibodies reactive with nucleoprotein (NP), envelope glycoprotein (GP), and secreted envelope glycoprotein (sGP) were characterized by immunofluorescence and radioimmunoprecipitation assays. Four antibodies reacting strongly with sGP and weakly with GP and two antibodies reacting with NP were not neutralizing. An antibody specific for GP neutralized Ebola virus to 50% at 0.4 μg/ml as the recombinant Fab fragment and to 50% at 0.3 μg/ml (90% at 2.6 μg/ml) as the corresponding whole immunoglobulin G1 molecule. The studies indicate that neutralizing antibodies are produced in infection by Ebola virus although probably at a relatively low frequency. The neutralizing antibody may be useful in vaccine design and as a prophylactic agent against Ebola virus infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody
Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S. W., Hendry, R. M., Dunlop, N., Nara, P. L., et al. (1994) · Science · doi:10.1126/science.7973652 · Cited by 1,100
Self-citationBurton, D. R., Barbas, C. F., Persson, M. A., Koenig, S., Chanock, R. M., & Lerner, R. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.10134 · Cited by 663
Self-citationSanchez, A., Trappier, S. G., Mahy, B. W., Peters, C. J., & Nichol, S. T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3602 · Cited by 552
Self-citationProcessing of the Ebola virus glycoprotein by the proprotein convertase furin
Volchkov, V. E., Feldmann, H., Volchkova, V. A., & Klenk, H.-D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5762 · Cited by 497
A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic Fever
Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., & Huggins, J. (1998) · The Journal of Infectious Diseases · doi:10.1086/515386 · Cited by 492
Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients
Mupapa, K., Massamba, M., Kibadi, K., Kuvula, K., Bwaka, A., Kipasa, M., Colebunders, R., Muyembe‐Tamfum, J. J., & the International Scientific and Technical Committee (1999) · The Journal of Infectious Diseases · doi:10.1086/514298 · Cited by 420
VOLCHKOV, V. E., BECKER, S., VOLCHKOVA, V. A., TERNOVOJ, V. A., KOTOV, A. N., NETESOV, S. V., & KLENK, H.-D. (1995) · Virology · doi:10.1006/viro.1995.0052 · Cited by 375
Jahrling, P. B., Geisbert, T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., & Peters, C. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/514310 · Cited by 269
Self-citationAn Introduction to Ebola: The Virus and the Disease
Peters, C. J., & LeDuc, J. W. (1999) · The Journal of Infectious Diseases · doi:10.1086/514322 · Cited by 260
Self-citationPrince, G. A., Horswood, R. L., & Chanock, R. M. (1985) · Journal of Virology · doi:10.1128/jvi.55.3.517-520.1985 · Cited by 245
Cited by
Feldmann, H., & Geisbert, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60667-8 · Cited by 1,374
Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
Carette, J. E., Raaben, M., Wong, A. C., Herbert, A. S., Obernosterer, G., Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., et al. (2011) · Nature · doi:10.1038/nature10348 · Cited by 1,303
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
Corti, D., Misasi, J., Mulangu, S., Stanley, D. A., Kanekiyo, M., Wollen, S., Ploquin, A., Doria-Rose, N. A., Staupe, R. P., Bailey, M., et al. (2016) · Science · doi:10.1126/science.aad5224 · Cited by 408
Ebola virus entry requires the host‐programmed recognition of an intracellular receptor
Miller, E. H., Obernosterer, G., Raaben, M., Herbert, A. S., Deffieu, M. S., Krishnan, A., Ndungo, E., Sandesara, R. G., Carette, J. E., Kuehne, A. I., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.53 · Cited by 335
Antiviral antibody responses: the two extremes of a wide spectrum
Hangartner, L., Zinkernagel, R. M., & Hengartner, H. (2006) · Nature Reviews Immunology · doi:10.1038/nri1783 · Cited by 314
Metadata
- Authors
- Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., Peters, C. J., Parren, P. W. H. I., & Burton, D. R.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 1999-07
- Volume
- 73
- Issue
- 7
- Pages
- 6024-6030
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2160359859
- Cited by
- 293
- References
- 25
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection. https://app.cochat.ai/papers/10.1128/jvi.73.7.6024-6030.1999
- The paper
- Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., Peters, C. J., Parren, P. W. H. I., & Burton, D. R. (1999). Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection. Journal of Virology. https://doi.org/10.1128/jvi.73.7.6024-6030.1999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
